Pfizer Inc. won a key ruling on Thursday that could upend a huge securities fraud case over the company’s marketing of the painkillers Celebrex and Bextra.
In a three-page order, U.S. District Judge Laura Taylor Swain in Manhattan granted a motion by Pfizer to exclude the testimony of Daniel Fischel, the former dean of the University of Chicago Law School and a frequent expert witness in high-profile securities cases. A class of Pfizer shareholders had hoped to use Fischel’s testimony to illustrate that Pfizer caused them billions of dollars’ worth of losses. But Swain ruled that Fischel’s testimony was unreliable because he didn’t properly explain a recent adjustment to his damages calculation.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
